Safety Reporting
Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.
4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.
The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.
The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.
4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.
4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).
Clinical Research News
Közelgő klinikai vizsgálatok
-
University of TennesseeWoodcock Institute for the Advancement of Neurocognitive Research and Applied...Még nincs toborzásMotoros készségek | Egészséges | Végrehajtó funkció
-
University of Texas Southwestern Medical CenterMerck Sharp & Dohme LLCMég nincs toborzásAnális laphámsejtes karcinóma
-
Universita di VeronaAzienda Ospedaliera Universitaria Integrata VeronaMég nincs toborzásRheumatoid arthritis | Degeneratív térdízületi betegségOlaszország
-
University of Wisconsin, MadisonAlkermes, Inc.Még nincs toborzás
-
Virginia Commonwealth UniversityMég nincs toborzás
-
Weill Medical College of Cornell UniversityNational Institute of Mental Health (NIMH); Icahn School of Medicine at Mount SinaiMég nincs toborzásKetamin | fMRI | Depresszió – súlyos depressziós rendellenesség | rTMS | Kezelés-rezisztens depresszió (TRD)Egyesült Államok
-
Weill Medical College of Cornell UniversityBD2 LLCMég nincs toborzásfMRI | Bipoláris zavar (BD) | rTMS | Bipoláris 1 depresszióEgyesült Államok
-
Xentria, Inc.Még nincs toborzás
-
Yale UniversityNational Institute of Mental Health (NIMH)Még nincs toborzás
-
Cambridge University Hospitals NHS Foundation TrustUniversity of CambridgeToborzásPheochromocytoma | Pheochromocytoma/Paraganglioma | Pheochromocytoma, metasztatikus | Pheochromocytoma Rosszindulatú | Feochromocytoma és paraganglioma (PPGL)Egyesült Királyság
-
Carl Zeiss Meditec-Dublin CoCeToborzásEpiretinális membrán | Retina betegség | Száraz életkorral összefüggő makuladegeneráció | Vitreoretinális rendellenesség | Macular Abnormalities | Intraretinal Hyporeflective Space | Subretinal Hyporeflective Space | IS/OS (Ellipsoid Zone) Disruption | Retinal Pigment Epithelium (RPE) Elevation | Retinal...Egyesült Államok
-
Celest Therapeutics (Shanghai) Co., Ltd.The First Affiliated Hospital of Anhui Medical UniversityToborzásCLDN18.2 pozitív szilárd daganatokKína
Clinical Research Jobs
-
Czechia - Brno
-
Belgium - Leuven
-
United Kingdom - Tranent
-
Romania - Bucharest
-
United StatesCanada - Québec - Quebec
-
United Kingdom - Guildford
-
India - Bengaluru
-
United States - North Carolina - Morrisville
-
China